In contrast, there were no co-occurring mutations of TP53, which is frequently mutated in endometrial serous and serous-like carcinomas, or of POLE, which is altered in ultramutated endometrial carcinomas, or of MSH2, MSH6 and MLH1, which are mutated in microsatellite unstable endometrial carcinomas (S2 Fig). Here, MSH6 is linked to endometrial carcinoma.